August 16, 2023 11:35 AM EDT
News Briefing

Pre­ci­sion Bio­Sciences hands glob­al rights to CAR-T can­di­date; Sagimet clos­es un­der­writer’s op­tion to buy stock

Paul Schloesser

Associate Editor

Pre­ci­sion Bio­Sciences said Tues­day night that it has closed a deal with Imu­gene, hand­ing off glob­al rights of its al­lo­gene­ic CAR-T can­di­date known as az­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times